Icatibant Viatris (Icatibant)

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. No fixed regimen is provided here; the prescriber will decide the appropriate amount and frequency for each individual.

Safety data for icatibant during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternative for hereditary angioedema is C1‑esterase inhibitor replacement therapy (plasma‑derived or recombinant). Icatibant directly blocks the bradykinin B2 receptor, offering a rapid, subcutaneous option, whereas C1‑INH replaces the deficient protein and is administered intravenously. Choice depends on patient preference, attack severity and clinical guidelines.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, consult the product label before use.

Icatibant is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional under medical supervision, following aseptic technique and the specific instructions provided with the product.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, airway edema that can compromise breathing, and significant hypotension. Patients should be monitored closely after the first dose, and any signs of allergic reaction or respiratory difficulty require immediate medical attention.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with uncontrolled cardiovascular disease, severe renal impairment, or those who are pregnant or breastfeeding unless the potential benefit outweighs the risk.